Is This the Last Surge for OvaScience?

Comments (3)

  1. Joseph says:

    Think of Ovasience as Tesla for fertility. At current levels, it is still a bargain. In a year, it can be $200/share (or more).


  2. John says:

    I totally agree, this stock is a breakthrough and some analysts already gave it a price target as $100!


  3. Elizabeth says:

    Your article is misleading about the AUGMENT treatment. AUGMENT requires ICSI in order to be able to inject the mitochondria into the egg. In addition, patients are still required to have hormonal injections with AUGMENT. You are confusing AUGMENT with a technology Ovascience is developing that is a long way off….Ovature.


Add Comment